| Expression pattern: |
UP |
| Associated gene: |
HDGF, Ago2 |
| Associated microRNA: |
miR-761 |
| Biological function: |
circMYH9 promotes CRC malignant behaviors, including cell viability, proliferation, cell cycle progression, migration and invasion, inhibits apoptosis, and counteracts Baicalin-induced anti-tumor effects. |
| Molecular mechanism: |
circMYH9 acts as a molecular sponge for miR-761 and up-regulates HDGF expression, forming a circMYH9/miR-761/HDGF ceRNA axis involved in Baicalin response in CRC. |
| Biological pathway or process: |
proliferation (promotes); cell cycle (promotes); apoptosis (inhibits); migration (promotes); invasion (promotes); ceRNA regulation (other); drug resistance (other) |
| Detected method: |
Q
|
| Validation methods: |
Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis; Transfection; CCK8; Colony Formation Assay; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Western Blot; Transwell Assay; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); In Vivo Animal Model |
| Clinical significance: |
circMYH9 was abnormally upregulated in CRC tissues and was suggested as a stable circRNA biomarker candidate, but no diagnostic or prognostic performance was reported. |
| Description: |
circMYH9 is up-regulated in colorectal cancer tissues and cell lines and is reduced by Baicalin treatment. Functionally, circMYH9 promotes malignant phenotypes and attenuates Baicalin-induced anti-tumor effects by sponging miR-761 and up-regulating HDGF in CRC cells. |
| Confidence score: |
0.795 |